| Bioactivity | KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses[1][2]. |
| Invitro | KYL peptide blocks the extracellular ligand-binding domain of EphA4, abolishes the Aβ-stimulated EphA4 tyrosine phosphorylation[2].KYL peptide abolishes the Aβ-triggered reduction of dendritic spines in cultured hippocampal neurons[2]. |
| Name | KYL peptide |
| CAS | 676657-00-4 |
| Shortening | KYLPYWPVLSSL |
| Formula | C74H108N14O17 |
| Molar Mass | 1465.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
KYL peptide
CAS: 676657-00-4 F: C74H108N14O17 W: 1465.73
KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor. KYL peptide binds to the ligand-binding domain
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.